• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒主要肽酶被类底物氮杂肽环氧化物抑制后的晶体结构

Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide.

作者信息

Lee Ting-Wai, Cherney Maia M, Huitema Carly, Liu Jie, James Karen Ellis, Powers James C, Eltis Lindsay D, James Michael N G

机构信息

Canadian Institute of Health Research Group in Protein Structure and Function, Department of Biochemistry, University of Alberta, Edmonton, Alta., Canada T6G 2H7.

出版信息

J Mol Biol. 2005 Nov 11;353(5):1137-51. doi: 10.1016/j.jmb.2005.09.004. Epub 2005 Sep 27.

DOI:10.1016/j.jmb.2005.09.004
PMID:16219322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7094542/
Abstract

The main peptidase (M(pro)) from the coronavirus (CoV) causing severe acute respiratory syndrome (SARS) is one of the most attractive molecular targets for the development of anti-SARS agents. We report the irreversible inhibition of SARS-CoV M(pro) by an aza-peptide epoxide (APE; k(inact)/K(i) = 1900(+/-400) M(-1) s(-1)). The crystal structures of the M(pro):APE complex in the space groups C2 and P2(1)2(1)2(1) revealed the formation of a covalent bond between the catalytic Cys145 S(gamma) atom of the peptidase and the epoxide C3 atom of the inhibitor, substantiating the mode of action of this class of cysteine-peptidase inhibitors. The aza-peptide component of APE binds in the substrate-binding regions of M(pro) in a substrate-like manner, with excellent structural and chemical complementarity. In addition, the crystal structure of unbound M(pro) in the space group C2 revealed that the "N-fingers" (N-terminal residues 1 to 7) of both protomers of M(pro) are well defined and the substrate-binding regions of both protomers are in the catalytically competent conformation at the crystallization pH of 6.5, contrary to the previously determined crystal structures of unbound M(pro) in the space group P2(1).

摘要

导致严重急性呼吸综合征(SARS)的冠状病毒(CoV)的主要肽酶(M(pro))是开发抗SARS药物最具吸引力的分子靶点之一。我们报道了一种氮杂肽环氧化物(APE;k(inact)/K(i)= 1900(±400)M⁻¹ s⁻¹)对SARS-CoV M(pro)的不可逆抑制作用。在空间群C2和P2₁2₁2₁中M(pro):APE复合物的晶体结构揭示了肽酶的催化性半胱氨酸145的S(γ)原子与抑制剂的环氧化物C3原子之间形成了共价键,证实了这类半胱氨酸肽酶抑制剂的作用模式。APE的氮杂肽成分以类似底物的方式结合在M(pro)的底物结合区域,具有出色的结构和化学互补性。此外,空间群C2中未结合的M(pro)的晶体结构表明,M(pro)两个原体的“N指”(N端残基1至7)定义明确,并且在6.5的结晶pH下,两个原体的底物结合区域处于催化活性构象,这与先前在空间群P2₁中确定的未结合M(pro)的晶体结构相反。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/77e1473c7375/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/4e8545fabc06/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/1241ca7b5786/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/34cc954a6166/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/3874e94d51c2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/d4b650bb2e8c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/be526766e992/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/77e1473c7375/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/4e8545fabc06/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/1241ca7b5786/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/34cc954a6166/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/3874e94d51c2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/d4b650bb2e8c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/be526766e992/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b0/7094542/77e1473c7375/gr7.jpg

相似文献

1
Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide.严重急性呼吸综合征冠状病毒主要肽酶被类底物氮杂肽环氧化物抑制后的晶体结构
J Mol Biol. 2005 Nov 11;353(5):1137-51. doi: 10.1016/j.jmb.2005.09.004. Epub 2005 Sep 27.
2
Crystal structures reveal an induced-fit binding of a substrate-like Aza-peptide epoxide to SARS coronavirus main peptidase.晶体结构揭示了一种类似底物的氮杂肽环氧化物与严重急性呼吸综合征冠状病毒主要蛋白酶的诱导契合结合。
J Mol Biol. 2007 Feb 23;366(3):916-32. doi: 10.1016/j.jmb.2006.11.078. Epub 2006 Dec 2.
3
Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.肽醛抑制剂挑战了 SARS-CoV 主蛋白酶的底物特异性。
Antiviral Res. 2011 Nov;92(2):204-12. doi: 10.1016/j.antiviral.2011.08.001. Epub 2011 Aug 11.
4
A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.严重急性呼吸综合征冠状病毒3C样蛋白酶活性位点中酶抑制和肽水解的机制性观点。
J Mol Biol. 2007 Aug 24;371(4):1060-74. doi: 10.1016/j.jmb.2007.06.001. Epub 2007 Jun 8.
5
Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.基于结构的严重急性呼吸综合征冠状病毒主要蛋白酶新型非肽抑制剂的药物设计与结构生物学研究
J Med Chem. 2006 Aug 24;49(17):5154-61. doi: 10.1021/jm060207o.
6
Mechanism for controlling the monomer-dimer conversion of SARS coronavirus main protease.严重急性呼吸综合征冠状病毒主要蛋白酶单体-二聚体转化的控制机制
Acta Crystallogr D Biol Crystallogr. 2013 May;69(Pt 5):747-55. doi: 10.1107/S0907444913001315. Epub 2013 Apr 11.
7
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.猫冠状病毒药物可抑制新型冠状病毒的主要蛋白酶并阻断病毒复制。
Nat Commun. 2020 Aug 27;11(1):4282. doi: 10.1038/s41467-020-18096-2.
8
Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold.从肽模拟物到氮杂十氢化萘支架开发SARS 3CL蛋白酶抑制剂的结构基础。
Biopolymers. 2016 Nov 4;106(4):391-403. doi: 10.1002/bip.22773.
9
pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses.严重急性呼吸综合征冠状病毒主要蛋白酶(M(pro))二聚体的pH依赖性构象灵活性:分子动力学模拟和多重X射线结构分析
J Mol Biol. 2005 Nov 18;354(1):25-40. doi: 10.1016/j.jmb.2005.09.012. Epub 2005 Sep 23.
10
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.氯氟乙酰胺基共价抑制剂用于严重急性呼吸综合征冠状病毒 2 3CL 蛋白酶的发现。
J Med Chem. 2022 Oct 27;65(20):13852-13865. doi: 10.1021/acs.jmedchem.2c01081. Epub 2022 Oct 13.

引用本文的文献

1
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.SARS-CoV-2 主蛋白酶(Mpro)抑制剂作为抗冠状病毒药物。
Biomolecules. 2024 Jul 4;14(7):797. doi: 10.3390/biom14070797.
2
Potential therapeutic target identification in the novel 2019 coronavirus: insight from homology modeling and blind docking study.2019新型冠状病毒潜在治疗靶点的鉴定:同源建模与盲对接研究的见解
Egypt J Med Hum Genet. 2020;21(1):44. doi: 10.1186/s43042-020-00081-5. Epub 2020 Oct 2.
3
αβ,α'β'-Diepoxyketones are mechanism-based inhibitors of nucleophilic cysteine enzymes.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.振荡模式下收集的X射线衍射数据的处理。
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase.新型严重急性呼吸综合征冠状病毒3C样蛋白酶非共价抑制剂的虚拟筛选
J Chem Inf Model. 2005 Jan-Feb;45(1):10-17. doi: 10.1021/ci049809b.
3
Molecular mechanisms of severe acute respiratory syndrome (SARS).严重急性呼吸综合征(SARS)的分子机制
αβ,α'β'-环氧酮是亲核半胱氨酸酶的基于机制的抑制剂。
Chem Commun (Camb). 2023 Oct 26;59(86):12859-12862. doi: 10.1039/d3cc02932h.
4
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.SARS-CoV 和 SARS-CoV-2 主要蛋白酶的结构与功能及其抑制作用:全面综述。
Eur J Med Chem. 2023 Nov 15;260:115772. doi: 10.1016/j.ejmech.2023.115772. Epub 2023 Aug 28.
5
P Glutamine isosteres in the design of inhibitors of 3C/3CL protease of human viruses of the class.人γ冠状病毒3C/3CL蛋白酶抑制剂设计中的P谷氨酰胺等排体
RSC Chem Biol. 2023 Jun 21;4(8):533-547. doi: 10.1039/d3cb00075c. eCollection 2023 Aug 3.
6
Green and rapid and instrumental one-pot method for the synthesis of imidazolines having potential anti-SARS-CoV-2 main protease activity.绿色、快速且仪器化的一锅法合成具有潜在抗SARS-CoV-2主要蛋白酶活性的咪唑啉。
Sustain Chem Pharm. 2023 Sep;34:101136. doi: 10.1016/j.scp.2023.101136. Epub 2023 Jun 5.
7
Pharmacophore Oriented MP2 Characterization of Charge Distribution for Anti-SARS-CoV-2 Inhibitor Nirmatrelvir.基于药效团的抗SARS-CoV-2抑制剂奈玛特韦电荷分布的MP2表征
J Mol Struct. 2023 Oct 15;1290:135871. doi: 10.1016/j.molstruc.2023.135871. Epub 2023 May 30.
8
Dock-able linear and homodetic di, tri, tetra and pentapeptide library from canonical amino acids: SARS-CoV-2 Mpro as a case study.基于标准氨基酸的可对接线性同系二肽、三肽、四肽和五肽文库:以SARS-CoV-2 Mpro为例进行研究。
J Pharm Anal. 2023 May;13(5):523-534. doi: 10.1016/j.jpha.2023.04.008. Epub 2023 Apr 15.
9
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.COVID-19 的潜在治疗方法:药物再利用和治疗干预。
J Pharmacol Sci. 2023 May;152(1):1-21. doi: 10.1016/j.jphs.2023.02.004. Epub 2023 Feb 15.
10
Unveiling mutation effects on the structural dynamics of the main protease from SARS-CoV-2 with hybrid simulation methods.利用混合模拟方法揭示 SARS-CoV-2 主蛋白酶结构动力学的突变效应。
J Mol Graph Model. 2023 Jun;121:108443. doi: 10.1016/j.jmgm.2023.108443. Epub 2023 Feb 22.
Respir Res. 2005 Jan 20;6(1):8. doi: 10.1186/1465-9921-6-8.
4
Generation of predictive pharmacophore model for SARS-coronavirus main proteinase.严重急性呼吸综合征冠状病毒主要蛋白酶预测药效团模型的生成
Eur J Med Chem. 2005 Jan;40(1):57-62. doi: 10.1016/j.ejmech.2004.09.013.
5
Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro.酮谷氨酰胺类似物作为严重急性呼吸综合征3CL蛋白酶强效抑制剂的合成与评价
J Med Chem. 2004 Dec 2;47(25):6113-6. doi: 10.1021/jm0494873.
6
Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease.严重急性呼吸综合征(SARS)冠状病毒主要蛋白酶的四级结构。
Biochemistry. 2004 Nov 30;43(47):14958-70. doi: 10.1021/bi0490237.
7
Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations.严重急性呼吸综合征冠状病毒3C样蛋白酶N端对于蛋白水解活性必不可少,但对于酶的二聚化并非如此。结合分子动力学模拟的生化和热力学研究。
J Biol Chem. 2005 Jan 7;280(1):164-73. doi: 10.1074/jbc.M408211200. Epub 2004 Oct 26.
8
High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase.高通量筛选鉴定出严重急性呼吸综合征冠状病毒主要蛋白酶的抑制剂。
Chem Biol. 2004 Oct;11(10):1445-53. doi: 10.1016/j.chembiol.2004.08.011.
9
Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics.通过化学遗传学鉴定严重急性呼吸综合征相关冠状病毒的新型小分子抑制剂。
Chem Biol. 2004 Sep;11(9):1293-9. doi: 10.1016/j.chembiol.2004.07.013.
10
Refinement of macromolecular structures by the maximum-likelihood method.用最大似然法优化大分子结构。
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55. doi: 10.1107/S0907444996012255.